- Home
- IRIX vs INAB Comparison
IRIX vs INAB Comparison
Compare IRIX & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRIX
- INAB
- Stock Information
- Founded
- IRIX 1989
- INAB 2016
- Country
- IRIX United States
- INAB United States
- Employees
- IRIX N/A
- INAB N/A
- Industry
- IRIX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- IRIX Health Care
- INAB Health Care
- Exchange
- IRIX Nasdaq
- INAB Nasdaq
- Market Cap
- IRIX 16.5M
- INAB 14.5M
- IPO Year
- IRIX 1996
- INAB 2021
- Fundamental
- Price
- IRIX $1.01
- INAB $2.30
- Analyst Decision
- IRIX
- INAB Strong Buy
- Analyst Count
- IRIX 0
- INAB 2
- Target Price
- IRIX N/A
- INAB $108.00
- AVG Volume (30 Days)
- IRIX 67.3K
- INAB 170.8K
- Earning Date
- IRIX 08-07-2025
- INAB 08-07-2025
- Dividend Yield
- IRIX N/A
- INAB N/A
- EPS Growth
- IRIX N/A
- INAB N/A
- EPS
- IRIX N/A
- INAB N/A
- Revenue
- IRIX $48,804,000.00
- INAB N/A
- Revenue This Year
- IRIX $9.61
- INAB N/A
- Revenue Next Year
- IRIX N/A
- INAB N/A
- P/E Ratio
- IRIX N/A
- INAB N/A
- Revenue Growth
- IRIX N/A
- INAB N/A
- 52 Week Low
- IRIX $0.78
- INAB $2.05
- 52 Week High
- IRIX $2.41
- INAB $27.30
- Technical
- Relative Strength Index (RSI)
- IRIX 61.37
- INAB 39.46
- Support Level
- IRIX $0.92
- INAB $2.10
- Resistance Level
- IRIX $1.01
- INAB $2.30
- Average True Range (ATR)
- IRIX 0.05
- INAB 0.14
- MACD
- IRIX 0.02
- INAB 0.11
- Stochastic Oscillator
- IRIX 100.00
- INAB 49.56
About IRIX IRIDEX Corporation
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.